Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.

@article{Joensuu2016CosteffectivenessOB,
  title={Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.},
  author={Jaana Tuulikki Joensuu and Kalle Aaltonen and Pasi Aronen and Tuulikki Sokka and Kari T Puolakka and Riitta Tuompo and Markku M Korpela and Mikko Vasala and Kirsti Ilva and Dan C. E. Nordstr{\"o}m and Marja Blom},
  journal={Rheumatology},
  year={2016},
  volume={55 10},
  pages={1803-11}
}
OBJECTIVE The aim of this study was to explore the cost-effectiveness of biological DMARDs (bDMARDs) compared with conventional synthetic DMARDs (csDMARDs) for RA using real-world data from Finnish registers. METHODS RA patients starting their first bDMARD and comparator patients using csDMARDs during 2007-11 were obtained from the National register of biologic treatments in Finland and the Jyväskylä Central Hospital patient records. Propensity score matching was applied to adjust for… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS